Halozyme Therapeutics | HALO - Stock


Halozyme Therapeutics reported $137.14M in Stock for its fiscal quarter ending in June of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amarin USD 164.07M 19.51M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Baxter International USD 2.26B 57M Jun/2026
Cara Therapeutics USD 900K 0 Mar/2025
Cytokinetics USD 380K 226K Jun/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Halozyme Therapeutics USD 137.14M 18.33M Jun/2026
Intrexon USD 287K 68K Dec/2022
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
MannKind USD 44.42M 4.75M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Pfizer USD 9.94B 722M Jun/2026
Rigel Pharmaceuticals USD 13.3M 2.88M Sep/2025
United Therapeutics USD 193.8M 15.5M Jun/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025